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Abstract: The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden
are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several
cancers even though no link with GEP-NETs was yet established. Our aim in this study was to
investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with
well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with
a control group (n = 96) derived from the general population in a case-control study. Patients presented
gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized
disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had
clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria.
Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’
waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and
p < 0.001, respectively). The likelihood of the association was higher when the number of individual
MetS components was greater than four. MetS and some individual MetS components including visceral
obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET.
This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
Keywords: gastroenteropancreatic neuroendocrine tumor; abdominal obesity; metabolic syndrome;
glucose abnormalities
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1. Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are considered a rare entity even
though a 6.5-fold increase in incidence was observed in the past four decades [1], which are believed
to be predominantly driven by the rising number of the incidental detection of low-stage tumors [2].
GEP-NETs are currently the second most frequent digestive tumor only surpassed by colorectal
cancer [3]. Grounded on the increasing knowledge related to the biology of the tumors accumulated
in the past two decades, a great effort has been made in order to establish guidelines for GEP-NETs
classification and management [4]. Nevertheless, despite the fact that significant advances were made
towards the understanding of the genetics and molecular mechanisms associated with NETs, very little
is known about the etiology of sporadic tumors or the reasons for the rising incidence observed over
the past several decades [5].
The possible link between obesity and cancer was first described in the 1940s even though the
molecular mechanisms underlying this association were only recently described [6,7]. Obesity is frequently
associated with insulin resistance (IR), which is related to a state of systemic and local low grade chronic
inflammatory state responsible for the activation of a number of signaling pathways involving hormone
control, cell proliferation, and immunity [6,7] that led to neoplastic transformation of cells.
Insulin resistance (IR), metabolic syndrome (MetS), and type 2 diabetes mellitus (T2DM) are now
well-established risk factors for many cancers including postmenopausal breast cancer, endometrial
cancer, colorectal cancer, and hepatocarcinoma [8]. Chronic inflammation is also a well-recognized
cancer promoter [9] such as chronic pancreatitis that leads to pancreatic cancer [10], ulcerative colitis
to colon cancer [11], and non-alcoholic steatohepatitis (NASH) for liver cancer [12].
Whether obesity and MetS could be involved in the etiology of GEP-NETs to the extent of
justifying the recent burden of the disease is unknown. This applies in particular to well-differentiated
(WD) GEP-NETs, corresponding to the World Health Organization (WHO) 2010 grade G1 and G2,
which have a natural history dramatically different from G3 poor-differentiated neuroendocrine
carcinoma (NEC) [13].
Thus, the aim of the current study was to evaluate the possible association between MetS and
MetS individual components with WD GEP-NETs by performing a case-control study comparing
data from patients from a large tertiary cancer center with a matched control group derived from the
background general population.
2. Results
2.1. Patients’ Characteristics
Table 1 provides the demographic, anthropometric, and clinical features of WD GEP-NET patients
and controls. Patients’ mean age at WD GEP-NETs diagnosis was 58.2 years and 62.4 years at the
time of a study assessment. There was a slight preponderance of males (52.1%) and the majority of
the patients lived within the area of our institution (45.8%). Most patients had previous diagnosis of
hypertension (63.5%), dyslipidemia (62.3%), or T2DM (17.7%). Family history of T2DM was present
in 48.1% of cases. A large percentage of patients were under blood pressure lowering drugs (50.5%),
lipid lowering medications (37.9%), statins (91.7%), and glucose lowering therapy (14.2%) including
dipeptidyl peptidase-4 (DPP-4) inhibitors and/or metformin (58.3%), sulfonylureas (16.7%), or insulin
(25.0%). Although there was no significant difference between WD GEP-NET patients and controls
concerning the use of glucose lowering therapy, the proportion of patients under BP or lipid lowering
therapy was significantly higher in patients than in controls (p < 0.001). There were no significant
differences between patients and controls concerning weight, body mass index (BMI), systolic blood
pressure (SBP), diastolic blood pressure (DBP), fasting plasma insulin (FPI), and Homeostasis Model
Assessment Insulin Resistance (HOMA-IR). Total cholesterol (TC) and LDL-cholesterol (LDL-c) levels
were significantly higher (p = 0.02 and p < 0.001, respectively) and HDL-c was significantly lower
(p = 0.001) in controls when compared to patients. Fasting plasma glucose (FPG) was significantly
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higher in patients than in controls (p < 0.001) despite the fact that 14.2% of the patients were under
glucose lowering therapy.
Table 1. Demographic, anthropometric, clinical, and biochemical features of patients with WD
GEP-NETs and controls.
Demographic and Clinical Features Patients (n = 96) Controls (n = 96) p
Age in years—mean (SD) 62.4 (11.20) 62.4 (12.1) 0.979
Age at Diagnosis in years—mean (SD) 58.2 (11.2) - -
Duration of the disease in months—mean (SD), (n = 92) 55.3 (37.5) - -
Gender—n (%)
Male 50 (52.1) 52 (54.2) 0.772
Female 46 (47.9) 44 (45.8)
Metabolic Treatment
Previous anti-hypertensive treatment (n = 95/71) 48 (50.5) 12 (16.9) <0.001
Previous anti-dyslipidemia treatment (n = 95/71) 36 (37.9) 7 (9.9) <0.001
Statins 33 (91.7) 6 (8.5) -
Fibrates 3 (8.3) 3 (3.2) -
Previous anti-diabetic treatment (n = 79) 12 (14.2) 3 (4.2) 0.102
Insulin sensitizers 7 (58.3) 3 (4,2)
Sulfonylureas 2 (16.7) - -
Insulin 3 (25.0) - -
Clinical Evaluation
Height, cm—median (IQR) 164.0 (14.5) 163.0 (39,0) 0.573
Weight, cm—mean (SD) 72.6 (13.6) 72.0 (13.3) 0.753
BMI, Kg/m2—mean (SD) 26.9 (4.2) 27.2 (4.1) 0.645
WC, cm—mean (SD) 94.9 (12.0) 93.0 (10.6) 0.236
SBP, mmHg—median (IQR) 135.0 (21.0) 130.0 (28.0) 0.247
DBP, mmHg—median (IQR) 75.5 (17.0) 70.5 (12.0) 0.203
Biochemical Evaluation
TC, mg/dL—mean (SD) 192.1 (44.4) 208.1 (49.8) 0.020
LDL-c, mg/dL—mean (SD) 114.1 (37.1) 139.6 (41.0) <0.001
HDL-c, mg/dL—mean (SD) 50.8 (13.1) 44.8 (12.3) 0.001
TG, mg/dL—median (IQR) 117.5 (78.5) 105.0 (77) 0.091
FPG, mg/dL—median (IQR) 101.0 (22.0) 88.5 (27.5) <0.001
FPI—median (IQR) 6.2 (5.0) 5.8 (6.0) 0.372
HOMA-R—median (IQR) 1.4 (1.6) 1.4 (1.6) 0.274
BMI (Body Mass Index), WC (waist circumference), SBP (systolic blood pressure), DBP (diastolic blood pressure),
TC (total cholesterol), TG (Triglycerides), FPG (fasting plasma glucose), FPI (fasting plasma insulin), HOMA-IR
(homeostasis model assessment insulin resistance), BMI (body mass index).
Subgroup analysis of patients comparing those that were under somatostatin analogues (SA)
treatment with those that were not (Table 2) did not show any significant differences between the
two groups regarding MetS (p = 0.746), WC (p = 0.198), TG levels (p = 0.503), HDL-c (p = 0.786),
FPG (p = 0.862), FPI (p = 0.187), and HOMA-RI (p = 0.438).
Table 2. Comparison of anthropometric and biochemical metabolic profile of WD GEP-NET patients
under somatostatin analogues (SA positive) treatment versus patients with no somatostatin analogue
exposure (SA negative).
Clinical Features SA Positive (n = 60) SA Negative (n = 36) p
WC (mean/SD) 96.2 (12.4) 96.7 (11.3) 0.198
TG (median (IQR)) 121.5 (73.3) 111.0 (91.5) 0.503
HDL (median (IQR)) 50.6 (13.3) 55.7 (12.9) 0.786
FPG (median (IQR)) 102.0 (22.0) 99.5 (20.0) 0.862
FPI (median (IQR)) 6.1 (4.0) 7.3 (9.0) 0.187
HOMA-R (median (IQR)) 1.4 (0.8) 1.5 (2.1) 0.438
WC (waist circumference), TG (Triglycerides), Fasting Glucose (FPG), FPI (fasting plasma insulin), HOMA-IR
(Homeostasis Model Assessment Insulin Resistance).
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The most frequent localization of the primary tumor was gastrointestinal (GI-NETs) in 75% of cases
(60.0% in the ileum, 40% non-ileum), which is followed by pancreatic NETs (pNETs) that represented
22.9% of cases while, in two cases, the PT localization was unknown. The tumor’s hormone secretion
profile was determined in the majority of the patients (90.6%) while 45.8% were found to be secreting
tumors presenting with carcinoid syndrome (93.2%) or sporadic gastrinomas (6.8%). WD GEP-NETs
were either grade G1 (66.7%) or G2 (27.1%) tumors. At presentation, 43.8% of patients were found to
have distant metastasis, 16.7% of patients had loco-regional disease, and 31.2% of patients had localized
disease, which included duodenal and colorectal NET polyps. Patients without distant metastasis
referred to our center after surgical removal of the PT without information concerning available lymph
nodes were considered to have an undetermined tumor stage (n = 8). WD GEP-NETs patients were
treated in accordance with established treatment guidelines with SA (62.5%), liver ablative therapies
including hepatic arterial embolization (TAE), radiofrequency (RF) and thermal ablation (TA) (29.5%),
or with Peptide Receptor Radio Nuclide Therapy (PRRNT) with 177Luthetium-DOTATATE in 7.0%.
Only one of the patients included was submitted to chemotherapy and no patients went on target
therapies (Table 3).
Table 3. WD GEP-NETs patient characteristics.
Localization of PT (n = 96) n (%)
GI-NET 72 (75.0)
Jejunum-ileum 45 (62.5)
Duodenum 10 (13.9)
Rectum 8 (11.1)
Appendix 5 (6.9)
Colon 2 (2.8)
Stomach 1 (1.4)
Ampulla 1 (1.4)
p-NET 22 (22.9)
Unknown (UK) 2 (2.1)
Hormonal Syndrome (n = 96)
Yes (93.2% carcinoid syndrome; 6.8% gastrinomas) 44 (45.8)
No 43 (44.8)
Unknown (UK) 9 (9.4)
Grading (WHO 2010)—n = 96
NETG1 64 (66.7)
NETG2 26 (27.1)
Unknown (UK) 6 (6.3)
Staging (ENETS)—(n = 96)
Local disease 30 (31.3)
Loco regional disease 16 (16.7)
Disseminated disease 42 (43.8)
Unknown (UK) 8 (8.3)
Past History
Family History of T2-DM (n = 81) 39 (48.1)
Hypertension (n = 96) 61 (63.5)
Dyslipidemia (n = 96) 60 (62.5)
T2DM (n = 96) 17 (17.7)
NET Treatment
Endoscopic therapy (n = 95) 11 (11.6)
Surgery (n = 96) 73 (76.8)
SA (n = 95) 60 (62.5)
Liver ablative therapies (n = 95) 28 (29.5)
PRRNT (n = 95) 7 (7.4)
Chemotherapy (n = 96) 1 (1.0)
Target therapies (n = 96) 0 (0.0)
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2.2. WD GEP-NETs Association with Obesity, Glucose Abnormalities, MetS, and IR
A strong association between WD GEP-NETs and MetS (p = 0.003) and MetS individual Joint
Interim Statement (JIS) criteria such as WC (p = 0.002), fasting TG (p = 0.011), FPG (p < 0.001),
and a moderate association with severe IR (p = 0.014) was found (Table 4).
Table 4. Association of MetS, MetS components, and IR with WD GEP-NETs and controls.
Clinical Features Pts. n (%) Controls n (%) OR (95% CI) p
Obesity Classification
Normal weight (BMI < 25 Kg/m2) 31 (32.3) 33 (34.4) 1
Excess weight (25 ≤ BMI < 30 Kg/m2) 41(42.7) 41 (42.7) 1.1 (0.6–2.0) 0.851
Obesity (BMI ≥ 30Kg/m2) 24 (25.0) 22 (22.9) 1.2 (0.5–2.5) 0.847
Classification of Glucose Abnormalities
Normal 62 (64.6) 71 (75.5) 1
IFG 14 (14.6) 4 (4.3) 4.0 (1.3–12.8) 0.013
T2DM 20 (20.8) 19 (20.2) 1.2 (0.6–2.5) 0.608
Metabolic Syndrome and Components
WC ≥ 80 (F)/94 (M) cm 55 (58.9) 34 (35.8) 2.5 (1.4–4.6) 0.002
BP ≥ 130/85 mmHg (or anti-hypertensive drugs) 63 (65.6) 61 (64.2) 1.06 (0.6–1.9) 0.838
C-HDL < 50 (F)/40 (M) mg/dL (or anti-dyslipidemia drugs) 52 (54.2) 48 (50.5) 1.6 (0.7–2.0) 0.615
TG ≥ 150 mg/dL (or anti-dyslipidemia drugs) 41(42.7) 24 (25.3) 2.2 (1.2–4.1) 0.011
FPG ≥ 100 mg/dL (or hypoglycemic drugs) 53 (55.2) 21 (22.1) 4.3 (2.3–8.2) < 0.001
Metabolic syndrome 58 (60.4) 37 (54.4) 2.4 (1.3–4.3) 0.003
IR Classification n (%)
Insulin sensitive (HOMA-IR < 3) 54 (56.3) 80 (85.1) 1
Insulin resistant (3 ≤ HOMA-IR < 5) 2 (3.0) 10 (10.6) 0.3 (0.1–1.4) 0.131
Very insulin resistant (HOMA-IR ≥ 5) 11 (11.5) 4 (4.3) 4.1 (1.2–13.5) 0.014
WC (waist circumference), BP (blood pressure), TG (triglycerides), FPG (Fasting Plasma Glucose)), Metabolic
Syndrome (Metabolic Syndrome), BMI (Body Mass Index), IFG (Impaired Fasting Glucose), T2DM (type 2 diabetes
mellitus), IR (insulin resistance), HOMA-IR (Homeostasis Model Assessment Insulin Resistance).
Moreover, the association increased significantly if four or five MetS individual components were
present (p = 0.024 and p = 0.032, respectively) (Figure 1).
Cancers 2018, 10, x 5 of 12 
 
2.2. WD GEP-NETs Association with Obesity, Glucose Abnormalities, MetS, and IR 
A strong association between WD GEP-NETs and MetS (p = 0.003) and MetS individual Joint 
Interim Statement (JIS) criteria such as WC (p = 0.002), fasting TG (p = 0.011), FPG (p < 0.001), and a 
moderate association with severe IR (p = 0.014) was found (Table 4). 
Table 4. Association of MetS, MetS components, and IR with WD GEP-NETs and controls. 
Clinical Features 
Pts.  
n (%) 
Controls  
n (%) OR (95% CI) p 
Obesity Classification     
Normal weight (BMI < 25 Kg/m2) 31 (32.3) 33 (34.4) 1  
Excess weight (25 ≤ BMI < 30 Kg/m2) 41(42.7) 41 (42.7) 1.1 (0.6–2.0) 0.851 
Obesity (B I ≥ 30Kg/m2) 24(25.0) 22(22.9) 1.2 (0.5–2.5) 0.847 
Classification of Glucose Abnormalities     
Normal 62 (64.6) 71 (75.5) 1  
IFG 14 (14.6) 4 (4.3) 4.0(1.3–12.8) 0.013 
T2DM 20(20.8) 9 (20.2) 1.2 (0.6–2.5) 0.608 
Metabolic Syndrome and Components     
WC ≥ 80 (F)/94 (M) cm 55 (58.9) 34 (35.8) 2.5 (1.4–4.6) 0.002 
BP ≥ 130/85 mmHg (or anti-hypertensive drugs) 63(65.6) 61 (64.2) 1.06 (0.6–1.9) 0.838 
C-HDL < 50 (F)/40 (M) mg/dL (or anti-dyslipidemia drugs) 52(54.2) 8 ( 0.5) 1.6 (0.7 2.0) 0.615 
TG ≥ 150 mg/dL (or anti-dyslipidemia drugs) 41(42.7) 24 (25.3) 2.2 (1.2–4.1) 0.011 
FPG ≥ 100 mg/dL (or hypoglycemic drugs) 53 (55.2) 21 (22.1) 4.3 (2.3–8.2) < 0.001 
Metab lic syndro e  8 (60.4) 37 (54.4) 2.4 (1. 4.3) 0. 3 
IR Classification n (%)     
Insulin sensitive (HOMA-IR < 3) 54 (56.3) 80 (85.1) 1  
Insul  r sistant (3 ≤ HOMA-IR < 5) 2 (3.0) 10 (10.6) 0.3 (0.1–1.4) 0.131 
Very insulin resistant (HOMA-IR ≥ 5) 11 (11.5) 4 (4.3) 4.1 (1.2–13.5) 0.014 
WC (waist circumference), BP (blood pressure), TG (triglycerides), FPG (Fasting Plasma Glucose)), 
Metabolic Syndrome (Metabolic Syndrome), BMI (Body Mass Index), IFG (Impaired Fasting Glucose), 
T2DM (type 2 diabetes mellitus), R (insulin resistance), HOMA-IR (Homeostasis Model Assessm nt 
Insulin Resistance). 
, t e a sociation increased significantly if fou  or fiv  MetS in ividual c mponents 
were present (p = 0.024 and p = 0.032, resp ctively) (Figure 1). 
 
Figure 1. Tumor risk depending on the presence of different numbers of individual MetS components. 
WD GEP-NETs (well-differentiated gastro-enteric-pancreatic neuroendocrine tumors), OR (odds 
ratio), CI (confidence interval), and MetS (Metabolic Syndrome). 
Figure 1. Tumor risk depending on the presence of different numbers of individual MetS components.
WD GEP-NETs (well-differentiated gastro-enteric-pancreatic neuroendocrine tumors), OR (odds ratio),
CI (confidence interval), and MetS (Metabolic Syndrome).
Cancers 2018, 10, 293 6 of 12
No association was found between WD GEP-NETs and BMI categories (p = 0.851 for excess weight
and p = 0.847 for obesity) or the presence of T2DM (p = 0.608) even though IFG was significantly more
frequent in patients than in controls (p = 0.013).
3. Discussion
Obesity and MetS are well established risk factors for several cancers even though whether there
is a link between these conditions and the recent burden of GEP-NETs is yet to be confirmed. The aim
of this study was to investigate whether there was an association between WD GEP-NETs and the
anthropometric and metabolic abnormalities that characterize MetS.
Our results show that WD GEP-NETs are associated with MetS and some of the MetS individual
components including elevated WC as surrogate for visceral obesity, fasting TG, and FPG. Moreover,
the association was significantly increased if four or five individual MetS components were present.
These findings also suggest WD GEP-NETs could also be associated with visceral obesity and severe IR
despite the fact that no clear association with obesity grade or T2DM was found. Therefore, this data
proposes that poor metabolic health, characterized by visceral obesity with altered glucose and lipid
metabolism, are the most likely risk determinants of WD GEP-NETs. Similar association profiles were
also described for other types of cancers including colon and rectal cancer [14], prostate cancer [15],
esophageal cancer [16], and even thyroid cancer [17].
One of the main strengths of this study was enrolling a reasonably large patient sample with
consistent data retrieval. All clinical and anthropometrical parameters were collected by the same
researcher for what is considered a rare disease. Matching controls for age, gender, and the area of
residence derived from the same background population ensured that these variables were similarly
distributed in both groups.
However, some limitations must be acknowledged. First, this was a single center-based
case-control study. Additionally, due to the tertiary nature of our referral center, the PT removal and
SA treatment initiation had already occurred when first observed at our institution in a considerable
proportion of patients. In these circumstances, data was obtained retrospectively to reassure patient
status before treatment. The sole exception was for FPI and FPG assessment that were performed while
on SA to minimize the hyperglycemic effect of the treatment sampling that was made immediately
before the next dosing [18].
Furthermore, as ongoing therapies were not subjected to match-control, the proportion of patients
under BP or lipid lowering therapy was significantly higher in WD-GEP-NETS patients than in
controls. This fact is unsurprising since subjects included in the control group were attended by
general practitioners while patients with NETs were attended at a tertiary center where treatment
intensification is more likely to occur. However, this dissimilarity between the groups should be
interpreted into context because, according to the established JIS criteria for MetS of the International
Diabetes Federation Task Force on Epidemiology and Prevention, ongoing treatment for any of the
individual parameters is considered equivalent to the positive individual criteria regardless of the
glucose, lipid, or blood pressure observed. Second, although the majority of patients under lipid
lowering therapies, were already under treatment when first observed, these therapies were mainly
statins (91.7%), which target mostly TG and LDL-C, which is less likely to interfere with triglycerides
and HDL-C levels and bias MetS syndrome individual criteria. Third, the fact that a larger percentage
of patients with NETs were under anti-hypertensive for a similar blood pressure profile further suggests
the dissimilarity between the MetS risk profile between the two groups.
Additional potential confounding factors such as a family history of cancer, cigarette smoking,
alcohol consumption, dietary habits, physical activity, occupation, and socioeconomic status were
not evaluated.
GEP-NETS were traditionally considered rare tumors. This paradigm has been changing over the
last four decades since a nearly seven-fold increase in GEP-NETS incidence was registered with
a current prevalence of 6.4 cases/100,000 inhabitants, which renders the ranking of the second
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most prevalent digestive neoplasia after colorectal cancer [1,3,5,19]. The reasons for the upsurge
in GEP-NETS have been mostly attributed to an increase in incidental discovery by the widespread
use of imaging techniques and improved medical skills while the actual mechanisms leading to the
recent burden have not attracted extensive investigation and remains largely unknown. Nonetheless,
epidemiological trends analysis using national statistics from several countries suggest that, to be able
to explain the difference in geographic and ethnic incidence patterns, both genetic and environmental
factors must be involved in the natural history of NETs [20].
Obesity has been known to be associated with cancer since the fourth decade of the 20th
century [21]. More recently, mechanisms that link obesity and cancer were also established and
particularly visceral adiposity was found to be linked with an increased risk of cancer independently
of BMI [22]. Given to the rarity and heterogeneity of GEP-NETs, epidemiological studies designed
to investigate the association between metabolic risk factors for the disease are lacking. Although
obesity is not yet an established risk factor for GEP-NETS, few studies demonstrated that BMI increases
pancreatic NET risk. A meta-analysis published in 2016 [23] describes two case-control studies linking
BMI and pNETs [24,25] with a pool risk of 1.37 (95% CI 0.25 to 7.69, p < 0.001). The prevalence of
incidental gastric NETs in obesity surgery candidates was found to be high [26] and the occurrence of
a pNET co-secreting GLP-1 and glucagon in a patient previously submitted for gastric bypass surgery
was also reported [27]. Although our data does not support an association between overweight or
obesity with WD GEP-NETs, visceral obesity as assessed by the WC criteria for MetS was associated
with an increased risk for WD GEP-NETs.
Few studies have addressed the putative association between glucose abnormalities with NETs
and the majority refers to pNETs. Diabetes is a hallmark of some rare functioning (RF) GEP-NET such as
glucagonomas, vasoactive intestinal polypeptide secreting tumors (VIPomas), and somatostatinomas
and is present in 70% of non-functioning pNETS [28]. Moreover, hyperglycemia can also be a side
effect of chemotherapy, SA, everolimus, and more recently PRRNT [18]. Our results show that not only
patients with pancreatic NETs but also GI-NETs especially small bowel have a higher prevalence of
MetS and glucose metabolism abnormalities. The present study points to a strong association between
all sites WD GEP-NETs and IFG even before the initiation of treatments that can cause altered glucose
homeostasis. This association was not exclusive of pNETs since it was also found in GI-NETs. No RF
GEP-NET characterized by hyperglycemia were included in this cohort. A strong association between
diabetes and pNETs with an estimate effect of 2.76 (95% CI 1.65–4.64, p = 0.090) was formerly found in
three case-control studies [24,25,29]. This effect was even higher in cases with recent onset diabetes
(OR 12.80, 95%CI 2.47–66.42, p = 0.135) and insulin treated patients (OR 4.80, 95% CI 1.20–18.90).
Two studies previously described the association between diabetes and tumors other than pNETs.
In women with pre-existing T2DM, gastric endocrine tumors (especially T1-GET) and small bowel
NETs were found to be increased seven-fold and two-fold, respectively [24]. Increased prevalence of
impaired glucose tolerance in patients with serotonin secreting metastatic NETs when compared to
non-secreting tumors was initially reported in 1975 [30]. Moreover, a recent publication from Valente et
al. concluded that non-recent diabetes was associated with an increased occurrence of pNETs especially
in metastatic disease and an advanced grade [31].
Our findings also support that there is an association of MetS with WD GEP-NETs. There is
accumulating evidence that visceral obesity, insulin resistance, hyperinsulinemia, chronic inflammation,
and T2DM can lead to increased cell proliferation, apoptosis inhibition, angiogenesis, and impaired
immunity [32,33]. MetS is a cluster of risk factors with a well-established association with
cardiovascular disease that was also demonstrated to be a modifiable risk factor for several cancers [34]
such as breast cancer in postmenopausal women (HR 1.89, 95% CI 1.29–2.77) [35]. Two studies from
South Korea concluded that there is an association between MetS and rectal NETs (r-NETs) (OR 1.768,
95% CI 1.071–2.918, p = 0.026) [36,37].
In the present study, no significant differences in FPI and HOMA-IR were found between patients
and controls. Nonetheless, the proportion of severe IR (HOMA-IR ≥ 5) was significantly higher in
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patients than in controls. Despite a large proportion of patients being under SA at the time of FPI
and an FG determination (60%), no differences in MetS criteria, MetS individual components, FPI,
HOMA-RI, and the proportion of insulin resistant and severe insulin resistant patients were found
between patients under SA treatment or were untreated, which suggests that our findings were not
influenced by SA (Table 2).
Our results also show that, although no differences were found in median TG levels between
patients and controls, the proportion of GEP-NET patients with TG ≥ 150 mg/dL was significantly
higher than in controls (p = 0.011). Despite the fact that low HDL-c was identified as an independent risk
factor for r-NETs in a South Korean cohort (OR 1.85, 95% CI 1.10–3.11, p = 0.021) [36,37], the unexpected
finding of lower TC and c-LDL levels as well as higher c-HDL levels in our patients’ cohort compared
to controls could be attributed to treatment intensification of patients with GEP-NETs when compared
to the general population since 37.2% of the patients vs. 9.9% of controls were under drug treatment for
dyslipidemia. Previously, only hypercholesterolemia was found to be a risk factor for rectal GEP-NETs
(OR 1.007, 95% CI 1.001–1.013; p = 0.016) in a single study [36]. This is in contrast with hypertension
since no association was found between hypertension and WD GEP-NETs.
4. Materials and Methods
Patients with confirmed WD GEP-NETs (n = 96) were recruited from the endocrine tumors clinic
of a large tertiary referral center for oncological diseases. The inclusion criteria were a confirmed
diagnosis of WD GEP-NETs by histopathology and/or PET-68Ga-DOTA-NOC. The exclusion criteria
were under 18 years of age when first diagnosed, familial GEP-NETs, NEC, and type 1 gastric endocrine
tumor (T1-GET) since these tumors have well-established etiology and distinctive behavior [13,38,39].
From a total number of patients recruited with confirmed WD GEP-NETs (n = 120) that consented
to participate in the study, those who did not fulfil the inclusion criteria or had insufficient data
for analysis were excluded (n = 24). The remainder of patients (n = 96) were then matched for age,
gender, and district of residence with a control group (n = 96) of the general population derived
from the PORMETs study, which is a nationwide epidemiological study designed to assess the
prevalence of MetS in the general population [40–42]. The present study was approved by the
National Data Protection Committee (CNPD 4906/2015) as well as the Institutional Ethics Committee
(IPO 366/2013). Patients gave their written informed consent to participate and were consecutively
enrolled as attending routine clinic appointments.
Data for analysis was collected through a face-to-face patient interview to assess the past medical
history of T2DM, hypertension, dyslipidemia, ongoing medications, and family history of T2DM while
height, weight, waist circumference (WC), and blood pressure (BP) measurements were collected
directly or indirectly, according to medical practice standards. Most patients were newly diagnosed
WD GEP-NETs patients who were referred to our center and the parameters used for the assessment
of metabolic syndrome refer to the time of diagnosis. For patients with longer disease duration
referred to our center after treatment initiation (surgery or somatostatin analogues), data was retrieved
from patient digital records from other institutions (hospital or general practice registries) to ensure
a minimum bias.
Biochemical data including FPG and the lipid profile were evaluated while off any active
anti-tumor treatment. The only exception was for FPG and FPI measurements that were used
for HOMA-IR calculation, which were assessed while on somatostatin analogues (SA) in those
patients who were already under oncological treatment. WD GEP-NETs were classified according
to primary tumor localization, the presence of the hormone secretion syndrome, the WHO 2010
grading system, and disease extension (ENETS TNM staging system) [43,44]. Cases with insufficient
data to allow grading were classified as WD GEP-NET if found to express somatostatin receptors on
PET-68Ga-DOTA-NOC (n = 6). Patients with metastatic tumors and carcinoid syndrome without any
visible pancreatic or thoracic lesions on imaging investigations were classified as having WD GEP-NET
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with an occult primary tumor (n = 2). No insulinoma or rare functional pancreatic NET presenting with
hyperglycemia such as glucagonoma, VIPoma or somatostatinoma were included in this study series.
Patients were classified into three categories according to the BMI, which included normal
weight (BMI < 25 Kg/m2), overweight (BMI 25–29.9 Kg/m2), or obese (BMI ≥ 30 Kg/m2) [45] and
according to FPG levels into normoglycemic (NG, FPG < 100 mg/dL) and impaired fasting glucose
(IFG, FPG 100–126 mg/dL) or T2DM (T2DM, FPG ≥ 126 mg/dL) [46]. MetS was classified, according
to the Joint Interim Statement (JIS) of NHLBI/AHA/WHF/IAS/IASO criteria [47]: WC ≥ 88 cm
(female) or 102 cm (male), BP ≥ 130 mmHg and/or 85 mmHg or previous history of high BP or under
BP lowering medication. HDL-cholesterol (HDL-c) < 40 mg/dL (male) or ≤50 mg/dL (female) drug
treatment for reduced HDL-c, triglycerides (TG) ≥ 150 mg/dL or under triglyceride lowering drugs,
and FPG ≥ 100 mg/dL or ongoing glucose-lowering drug treatments.
Insulin was determined by an automated enzyme-labeled chemiluminescent immune metric
solid-phase assay (IMMULITE 2000). IR was assessed by HOMA-IR index calculated using the formula
FPI (µU/mL)/FPG (mg/dL)/405 [19]. IR cut-offs were based on Matthews [48] definition: <3 (insulin
sensitive), ≥ 3 < 5 (IR) and ≥ 5 (severe IR).
Statistical analysis was performed using PASW 18.0. Categorical and continuous variables
were summarized using descriptive statistics (frequencies for categorical, mean/standard deviation
or median/interquartile range for continuous, as appropriate). Proportions were compared by the
Chi-squared or Fisher Exact test. Means were compared using the t-test or ANOVA while medians were
compared using the Mann-Whitney or Kruskal-Wallis tests. Unconditional logistic regression models
were used to evaluate the odds of developing GEP-NET, according to weight, glucose abnormalities,
IR, and MetS criteria. A level of significance of 0.05 was adopted.
5. Conclusions
In conclusion, our findings show that WD GEP-NETS are associated with MetS, elevated WC,
elevated FPG, elevated TG, and severe IR. These results are a breakthrough toward understanding the
recent WD GEP-NET “epidemic” since the association of the anthropometric, clinical, and biochemical
abnormalities that characterize MetS or IR with these specific tumors, according to the primary
location, the hormonal functional status, and grading or staging that had not been previously reported.
Although requiring confirmation in larger scale studies, these novel findings could provide crucial
insight toward the understanding of putative mechanisms leading to disease and prove important to
establish targeted preventive and treatment interventions [49] by addressing cancer as a metabolic
disease [50].
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